Skip to main content

PATh PDX/CDX & Surgical Facility

PATh PDX Facility 3D Render
3D render of
B-cell lymphoma
(highlighted in red).

The Progressive Assessment of Therapeutics (PATh) PDX Facility was established to provide comprehensive services and facilities to further the development and characterization of patient-derived xenograft (PDX) cancer models. PDX models using the NOD.Cg-PrkdcscidIl2rgtm1Wjl/SzJ (NSG) immunodeficient mice provide the most clinically relevant tumor models, which faithfully recapitulate the original tumor histology, genetic profile, and response/resistance to therapy.

The advantages associated with PDX mouse models include:

  • Ability to more easily establish novel tumor lines (Human, Canine, etc...)
  • Ability to test drug sensitivity in an in vivo model
  • Simple subcutaneous engrafting technique
  • Improved predictability of treatment outcomes and prognosis
  • Potential applications in personalized precision medical treatments
  • Ease of access to the subcutaneous tumor for biopsy
  • Preserved tumor heterogeneity
  • Allows for effective chronological tumor size monitoring

Our facility has extensive infrastructure to provide our clients with a full array of services ranging from the delivery of NSG mice to helping design and run preclinical trials with MR imaging. The PATh program operates on a cost recovery model, which allows us to pass on significant savings to the end user, some of which include animal costs and MR imaging time. PATh services are available to all Cornell and Weill Cornell investigators, outside institutions, industry, and private organizations.


  1. Methionine metabolism controls the B cell EBV epigenome and viral latency. Cell Metab. 2022 Sep 6;34(9):1280-1297.e9. PMID: 36070681
  2. Combined EZH2 and Bcl-2 inhibitors as precision therapy for genetically defined DLBCL subtypes. Blood Adv. 2020 Oct 27;4(20):5226-5231. PMID: 33104794
  3. Exploring the In Vivo and In Vitro Anticancer Activity of Rhenium Isonitrile Complexes. Inorg Chem. 2020 Jul 20;59(14):10285-10303. PMID: 32633531
  4. MYC Controls the Epstein-Barr Virus Lytic Switch. Mol Cell. 2020 May 21;78(4):653-669.e8. PMID: 32315601
  5. Epigenetic reprogramming sensitizes immunologically silent EBV+ lymphomas to virus-directed immunotherapy. Blood. 2020 May 21;135(21):1870-1881. PMID: 32157281